RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer

[1]  L. Lackner,et al.  Fission and fusion machineries converge at ER contact sites to regulate mitochondrial morphology , 2020, The Journal of cell biology.

[2]  P. Walter,et al.  Misfolded proteins bind and activate death receptor 5 to trigger apoptosis during unresolved endoplasmic reticulum stress , 2020, eLife.

[3]  P. Steeg,et al.  MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer , 2019, Breast Cancer Research.

[4]  P. Johnston,et al.  Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy , 2018, JCO precision oncology.

[5]  Elisa Ficarra,et al.  Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer , 2017, Nature Communications.

[6]  J. Downing,et al.  Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia , 2016, Oncogene.

[7]  Rodrigo Dienstmann,et al.  Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells , 2016, bioRxiv.

[8]  Ah Ram Lee,et al.  Hepatitis B virus–triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response , 2016, Autophagy.

[9]  D. Largaespada,et al.  RALB provides critical survival signals downstream of Ras in acute myeloid leukemia , 2016, Oncotarget.

[10]  Jin Myung Choi,et al.  Potentiation of TRAIL killing activity by multimerization through isoleucine zipper hexamerization motif , 2016, BMB reports.

[11]  G. Lahav,et al.  Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing , 2016, Cell.

[12]  Dong Eun Kim,et al.  Chloroquine enhances TRAIL-mediated apoptosis through up-regulation of DR5 by stabilization of mRNA and protein in cancer cells , 2016, Scientific Reports.

[13]  Marc Peeters,et al.  Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer , 2015, Clinical Cancer Research.

[14]  M. Salto‐Tellez,et al.  EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer , 2015, Clinical Cancer Research.

[15]  T. P. Neufeld,et al.  Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion , 2015, Autophagy.

[16]  John C. Hunter,et al.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations , 2015, Molecular Cancer Research.

[17]  C. Der,et al.  Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery? , 2015, Clinical Cancer Research.

[18]  P. Johnston,et al.  HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL , 2015, Clinical Cancer Research.

[19]  Emmanuel C. Alozie,et al.  Promises and Challenges , 2015 .

[20]  A. Tolcher,et al.  Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK , 2014, Clinical Cancer Research.

[21]  P. Poulikakos,et al.  Targeting RAS–ERK signalling in cancer: promises and challenges , 2014, Nature Reviews Drug Discovery.

[22]  C. Der,et al.  Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame. , 2014, Biochimica et biophysica acta.

[23]  David L. Brautigan,et al.  Discovery and characterization of small molecules that target the GTPase Ral , 2014, Nature.

[24]  R. Bernards,et al.  RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. , 2014, Cell reports.

[25]  Xiaolei Zhang,et al.  Ral GTPase Down-regulation Stabilizes and Reactivates p53 to Inhibit Malignant Transformation , 2014, The Journal of Biological Chemistry.

[26]  P. Johnston,et al.  ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. , 2014, Cell reports.

[27]  Jing Wang,et al.  An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition , 2014, Nature Cell Biology.

[28]  P. Johnston,et al.  Differential affinity of FLIP and procaspase 8 for FADD’s DED binding surfaces regulates DISC assembly , 2014, Nature Communications.

[29]  F. Hirsch,et al.  Contributions of KRAS and RAL in Non–Small-Cell Lung Cancer Growth and Progression , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  Baolin Zhang,et al.  Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5 , 2013, Oncotarget.

[31]  Herren Wu,et al.  Multivalent Scaffold Proteins as Superagonists of TRAIL Receptor 2–Induced Apoptosis , 2013, Molecular Cancer Therapeutics.

[32]  Mira Ayadi,et al.  Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.

[33]  G. Stamp,et al.  Genetic Deletion of RALA and RALB Small GTPases Reveals Redundant Functions in Development and Tumorigenesis , 2012, Current Biology.

[34]  C. Fuchs,et al.  A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. , 2012 .

[35]  Garrett M. Dancik,et al.  Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. , 2012, Cancer research.

[36]  F. Bosch,et al.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer , 2012, Nature Medicine.

[37]  W. El-Deiry,et al.  Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction , 2011, Cancer biology & therapy.

[38]  D. Lambrechts,et al.  Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet.

[39]  Harpreet Wasan,et al.  Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet. Oncology.

[40]  M. White,et al.  RalB and the Exocyst Mediate the Cellular Starvation Response by Direct Activation of Autophagosome Assembly , 2011, Cell.

[41]  T. Ørntoft,et al.  Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer , 2009, Clinical Cancer Research.

[42]  G. Gores,et al.  Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. , 2009, Gastroenterology.

[43]  T. Wilson,et al.  Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells , 2009, Oncogene.

[44]  Baolin Zhang,et al.  TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5 , 2008, Molecular Cancer Research.

[45]  W. Franklin,et al.  Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. White,et al.  Ral GTPases and cancer: linchpin support of the tumorigenic platform , 2008, Nature Reviews Cancer.

[47]  Eun Hee Kim,et al.  Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. , 2007, Cancer research.

[48]  K. Kelly,et al.  Activation of the RalGEF/Ral Pathway Promotes Prostate Cancer Metastasis to Bone , 2007, Molecular and Cellular Biology.

[49]  S. Adam,et al.  Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells , 2006, Current Biology.

[50]  C. Sousa.  Faculty Opinions recommendation of RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. , 2006 .

[51]  M. White,et al.  RalB GTPase-Mediated Activation of the IκB Family Kinase TBK1 Couples Innate Immune Signaling to Tumor Cell Survival , 2006, Cell.

[52]  D. Lawrence,et al.  Death-receptor activation halts clathrin-dependent endocytosis , 2006, Proceedings of the National Academy of Sciences.

[53]  P. Johnston,et al.  Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non–small cell lung cancer cells , 2006, Molecular Cancer Therapeutics.

[54]  D. Theodorescu,et al.  RalA and RalB: antagonistic relatives in cancer cell migration. , 2005, Cancer research.

[55]  S. Gibson,et al.  Transcription Factor NF-κB Differentially Regulates Death Receptor 5 Expression Involving Histone Deacetylase 1 , 2005, Molecular and Cellular Biology.

[56]  M. Shipitsin,et al.  Activation of RalA is critical for Ras-induced tumorigenesis of human cells. , 2005, Cancer cell.

[57]  J. Cedarbaum.  Survival , 2004 .

[58]  R. Weinberg,et al.  Species- and cell type-specific requirements for cellular transformation. , 2004, Cancer cell.

[59]  C. Der,et al.  Distinct requirements for Ras oncogenesis in human versus mouse cells. , 2002, Genes & development.

[60]  W. El-Deiry,et al.  Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site , 2000, Oncogene.

[61]  A. Kikuchi,et al.  The post‐translational modifications of Ral and Rac1 are important for the action of Ral‐binding protein 1, a putative effector protein of Ral , 1997, FEBS letters.

[62]  C. Der,et al.  Activation and involvement of Ral GTPases in colorectal cancer. , 2011, Cancer research.

[63]  E. Chiorean.  Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011 .

[64]  Christina Falschlehner,et al.  TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. , 2009, Advances in experimental medicine and biology.